News Conference News AHA 2017 Continuing NOACs During Device Surgery Does Not Reduce Pocket Hematoma Todd Neale November 15, 2017
News Conference News AHA 2017 GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS Yael L. Maxwell November 14, 2017
News Conference News AHA 2017 Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear Todd Neale November 14, 2017
News Conference News AHA 2017 Angiography, Revascularization Safe in Acute MI Patients Taking OACs for Atrial Fibrillation Michael O'Riordan November 13, 2017
News Conference News AHA 2017 AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More Shelley Wood November 09, 2017
News Conference News VIVA 2017 Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients L.A. McKeown September 11, 2017
News Conference News ESC 2017 EMANATE: Another NOAC Shown to Be Safe, Effective in the Setting of Cardioversion for A-fib Todd Neale September 05, 2017
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Conference News TVT 2017 Valve Leaflet Thrombosis: Treat It or Leave It Be? Shelley Wood June 19, 2017
News Conference News ACC 2017 RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest Yael L. Maxwell March 20, 2017
News Conference News ACC 2017 Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe Todd Neale March 18, 2017
News Conference News ACC 2017 Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE L.A. McKeown March 18, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017
News Conference News ISC 2017 NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin Todd Neale March 01, 2017